Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

By R. Arriagada, B. Bergman, A. Dunant, T. le Chevalier, Jean-Pierre Pignon, J. Vansteenkiste. New England Journal of Medicine, 2004

2,236 citations recorded by the source corpus.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/62d1f0fb331633d73360aae353a52bf19c465d21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Jemal

In Pulmonary and Respiratory Medicine

1. A. Jemal
2. Elizabeth E. Ward

In Surgery

1. A. Jemal
2. Elizabeth E. Ward

Citations in the corpus

• MicroRNA signature predicts survival and relapse in lung cancer. (2008, background): “…to standard surgery in order to improve the treatment outcome of NSCLC. Cisplatin-based adjuvant chemotherapy was recently reported to be effective for improvement of survival of NSCLC patients after surgical resection (The International Adjuvant Lung Cancer Trial Collaborative Group, 2004).”
• Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival (2004, background): “Progress in the treatment of lung cancer has been extremely limited.(49,50) Greater than 50% of cases are 18 CANCER July 1, 2004 / Volume 101 / Number 1”